Von Eschenbach's Vision Of Big Pharma
This article was originally published in RPM Report
Executive Summary
FDA Acting Commissioner Andrew von Eschenbach's tells pharmaceutical companies they're in the "solutions" business, not the drug business. Von Eschenback spoke at The RPM Report's FDA/CMS Summit in December.
You may also be interested in...
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
As DC Speculates on Democrats in 2009, Some Old FDA Hands Come Into View
No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.
FDA's Revolving Door: Crawford Out, von Eschenbach In
National Cancer Institute director Andrew von Eschenbach has succeeded Lester Crawford as FDA commissioner. We spoke to three Wall streeters--two sell-side, one buy side--about what the succession means for investors.